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Abstract
Background: Pemetrexed is widely used for the treatment of advanced non-squamous non-small-cell lung cancer
(NSCLC). However, factors that can predict the benefits of pemetrexed therapy have not yet been defined.
Methods: We compared the clinical and molecule pathological characteristics of good and poor responders
among a cohort of 1,848 non-squamous NSCLC patients who had received at least two cycles of pemetrexed
therapy between November 2006 and February 2015. Among these cases, 92 good responders who were the top
5 % in terms of progression-free survival (PFS) and 222 poor responders who had progressive disease after only
2 cycles of therapy were selected for the analysis.
Results: The median PFS of the good responders was 29.9 months (range; 20.9–90.0) and the median number of
cycle was 37 (range; 18–129). Although 53.5 % of patients showed stable disease (SD), this response was sustained
(median PFS in SD, 29.6 months). A never-smoking status was related to better survival outcome, whereas EGFR
mutation, two or more metastatic sites, and intra-abdominal metastasis were each associated with a poor PFS. ALK
translocation showed a tendency for a positive impact on response to pemetrexed, whereas metastatic lesion to
liver, adrenal gland or bone showed a tendency for a negative impact despite not reaching our threshold for
statistical significance.
Conclusions: Predictive factors, such as smoking status, the status of genetic alteration and tumor burden, should
be considered when administering pemetrexed therapy for non-squamous NSCLC.
Keywords: Pemetrexed, Non-small-cell lung cancer, Prognosis, Progression-free survival, EGFR, Anaplastic lymphoma
kinase
Background
Lung cancer is the leading cause of death worldwide. In
Korea, 40.6 % of lung cancer patients have a metastatic
lesion at the time of diagnosis [1]. Despite progress in the
understanding of cancer biology and development of new
therapeutic agents, the 5-year total survival rate for lung
cancer remains 19.7 % overall and drops to 4.8 % in
patients with a metastatic lesion at the time of diagnosis
[1]. Therefore, optimal treatments to improve the outcomes
of patients with advanced lung cancer are still needed.
Pemetrexed is a multi-targeting antifolate that can
inhibit thymidylate synthase (TS) and other folate-
dependent enzymes that are involved in purine and pyr-
imidine synthesis. Pemetrexed has been widely used to
treat patients with non-squamous non-small-cell lung
cancer (NSCLC) because two separate phase III trials of
this drug have reported prolonged survival in patients
with non-squamous cell carcinoma compared with those
with squamous cell carcinoma [2, 3]. Other than histo-
logic diagnoses, some factors related to the efficacy of
pemetrexed have been suggested. For example, sex was
found to have a prognostic impact on survival in a phase
III trial [4]. Additionally, never-smoker, anaplastic
lymphoma kinase (ALK) gene rearrangement, low tumor
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TS RNA level, thyroid transcription factor-1 (TTF-1)
expression and low serum leptin level were associated
with a good response to pemetrexed in previous studies
[4–10]. However, because most earlier studies did not
primarily focus on the pemetrexed response, we believe
that more investigations aimed at identifying factors that




Since pemetrexed was approved for the treatment for
non-squamous NSCLC in Korea at November 2006, we
identified non-squamous NSCLC patients who received
a pemetrexed-containing regimen between November
2006 and February 2015 at Asan medical center, Seoul,
South Korea. Patients were arranged in order of the
duration of pemetrexed therapy. Among these cases, pa-
tients who had been given pemetrexed once were
excluded, because they were more likely to be lost to
follow-up for several reasons other than experiencing
rapid progression of the disease. Most of these patients
were transferred to hospice facility or rejected to receive
further chemotherapy after initiation of pemetrexed
therapy. Since we intended to evaluate the efficacy of
pemetrexed in the current study, we selected patients
who received two or more cycles of pemetrexed and
underwent follow-up imaging study. Additionally, there
was a strong suspicion that some of those individuals
had been given pemetrexed despite showing a poor per-
formance status, due to the high tolerability and low
toxicity of this drug; however, those patients eventually
should have been discontinued treatment because of
their performance status [11]. We also excluded patients
for whom treatment was discontinued for reasons other
than disease progression, such as a poor performance
status, infection, transfer to another hospital, and
dropout. Finally, of the remaining patients, good
responders (top 5 percent) and poor responders
(bottom 5 percent) were planned to be selected for
comparison in our present analyses. The study design
was approved by the Institutional Review Board of
Asan Medical Center, which waived the requirement
for informed consent due to the retrospective nature
of the analysis.
Baseline and treatment assessments
We retrospectively reviewed clinicopathological data and
follow-up information contained in the archived medical
records in April 2015. The date of data cutoff was
February 28, 2015. Tumor histology was classified by pa-
thologists using the standard World Health Organization
criteria. We have examined the expression of TTF-1
using immunohistochemistry (1:200 dilution; Novocastra
Lab., Newcastle, UK). ALK status was determined by the
Vysis ALK Break Apart FISH probe kit (Abbott Molecu-
lar, Inc., Abbott Park, IL, USA). We analyzed epidermal
growth factor receptor (EGFR) mutations within exons
18 to 21 and Kirsten rat sarcoma viral oncogene homo-
log (KRAS) mutations by a direct DNA sequencing
method using an automatic ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
Patients were administered pemetrexed alone or in
combination with platinum or non-platinum agents at
a dose of 500 mg/m2 every 3 weeks. Maintenance
pemetrexed therapy after 4 cycles of pemetrexed-
platinum was considered as combination therapy. To
evaluate tumor responses, chest radiography was per-
formed during every cycle, and chest computed tomog-
raphy was performed every 2 to 3 cycles. If a patient
was suspected to have a new extrapulmonary lesion,
we immediately performed additional procedures,
such as abdominal computed tomography, magnetic
resonance imaging, bone scintigraphy, and positron
emission tomography. Progression-free survival (PFS)
was defined as the time from pemetrexed commencement
to either documented disease progression or death
from any cause. For patients without evidence of
disease progression at the date of data cutoff, patients
in the good responder group were censored at the
time of data cutoff. Disease status was assessed based
on the Response Evaluation Criteria in Solid Tumors
version 1.1 [12].
Statistical analysis
Categorical variables were analyzed using either Pearson’s
chi-square test or Fisher’s exact test and continuous
variables were analyzed using either Student t-test or
Mann–Whitney test. Variables selected by univariate ana-
lysis (p <0.1) were evaluated in a multivariate analysis
using the Cox proportional hazard model. All tests for sig-
nificance were two-sided, and all variable with a p-value
<0.05 were considered to be significant. All statistical ana-
lyses were performed with SPSS software version 21.0
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
From November 2006 to February 2015, a total of 2,310
non-squamous NSCLC patients received pemetrexed-
containing chemotherapy. Among these patients, 462
patients met the exclusion criteria. Of the remaining
1,848 patients, the bottom 14 % (252 patients) discontin-
ued treatment after receiving two cycles of pemetrexed-
containing treatment because of disease progression in
222 cases, transfer to another hospital in 16 cases, a
poor performance status in 7 cases, and pneumonia in
another 7 cases. As pemetrexed was given in same cycle
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to those bottom 12 % of overall patients, a final cohort
included 314 patients; the top 5 % (92 patients) and the
bottom 12 % (222 patients) (Fig. 1). We termed these pa-
tient groups as good responders and poor responders,
respectively.
The baseline demographic and clinical characteristics of
the patients are presented in Table 1. The mean age of the
314 patients was 59.1 ± 10.1 years old. Female (P = 0.009)
and never smokers (P = 0.015) were significantly predom-
inant in the good responder group compared with the
poor responder group. Among the 314 patients, 263
(83.8 %) received pemetrexed alone, 34 (10.8 %) received
pemetrexed in combination with a platinum agent, and 17
(5.4 %) received pemetrexed in combination with a non-
platinum agent. The number and types of regimens used
prior to pemetrexed were not significantly different be-
tween groups.
Efficacy
All patients in the poor responder group experienced
disease progression after receiving two cycles of
pemetrexed-containing therapy, and their median PFS
was 1.4 months (range, 0.7–2.8). By contrast, the median
PFS of the good responder group was 29.9 months
(range, 20.9–90.0) and the median cycle number was 37
(range, 18–129). Additionally, 46.7 % of the good re-
sponders experienced a partial response and 53.3 % of
them exhibited a stable disease.
Histology and gene alterations
The histological and genetic disease characteristics are
presented in Table 2. Most of the patients (285/314,
90.8 %) had adenocarcinoma and 24 patients (7.6 %) had
NSCLC-not otherwise specified. Among the 57 cases in
which the histological subtypes were identified, mucin-
ous adenocarcinoma (22/57, 38.6 %) was the most fre-
quent type, followed by acinar (13/57, 22.8 %) and
papillary (13/57, 22.8 %) types. Some characteristics of
good responders, such as the level of differentiation,
TTF-1 expression and gene alterations, were signifi-
cantly different from those of poor responders. A total
of 46.1 % of poor responders had EGFR mutation, while
16.7 % of good responder had EGFR mutation (P <0.001).
In contrast to EGFR mutation, ALK translocation was
more frequently seen in the good responder group (22.2 %
versus 4.2 %, P <0.001).
Tumor burden and site of metastasis
The median number of metastatic sites was 1 (range, 0–5)
in good responders and 2 (range, 0–7) in poor responders.
Consequentially, patients with two or more metastatic
sites were significantly more likely to be included in the
poor responder group (P <0.001). The contralateral
lung was the most common metastatic site, followed
by the pleura, bone, brain, adrenal gland and liver.
The poor responders had significantly more distant
metastases other than contralateral lung or pleura,
compared with the good responders (72.5 % versus
44.6 %, P <0.001). A total of 21.7 % of patients had
undergone previous surgical therapy, including 40.2 % of
the good responders and 14.0 % of the poor responders
(P <0.001) (Table 3).
Prognostic factors predicting efficacy of pemetrexed
When parameters were analyzed by univariate analysis
(P <0.1), sex, smoking status, level of differentiation, his-
tory of previous surgical therapy, gene alteration, tumor
burden and sites of metastasis were revealed as signifi-
cant prognostic factor predicting efficacy of pemetrexed
(Fig. 2). These parameters were put in multivariate ana-
lysis by Cox regression model. As a result, never smok-
ing status (hazard ratio [HR], 1.997; 95 % confidence
interval [CI], 1.442–2.766; P <0.001), EGFR mutation
(HR, 0.520; 95 % CI, 0.377–0.718; P <0.001), presence of
two or more metastatic sites (HR, 0.668; 95 % CI, 0.471–
0.946; P = 0.023) and presence of intraabdominal meta-
static lesion (HR, 0.590; 95 % CI, 0.410–0.847; P = 0.004)
were independent prognostic factor predicting efficacy
of pemetrexed containing regimen (Table 4).
Discussion
This is the first study to compare the characteristics of
good responders and poor responders to pemetrexed
therapy directly. Our current study findings demon-
strated that smoking status, EGFR mutation, tumor
burden and intra-abdominal metastasis are predictive
factors for the response of these lung cancer patients to
pemetrexed. In addition to EGFR mutation, molecular
Fig. 1 Distribution of non-small-cell lung cancer patients. Distribution
of non-small-cell lung cancer patients arranged in order of the duration
of pemetrexed therapy. The dotted lines indicate the cutoff for the top
5 % and bottom 12 % of patients
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genetic factors, such as ALK translocation and wild-type
for EGFR/ALK/KRAS, were more frequently seen in the
good responder group.
An activating EGFR mutation has been reported in vari-
ous studies not to confer a survival benefit for any chemo-
therapeutic regimen other than tyrosine kinase inhibitors,
with a median PFS of 5.8 months as a first-line and of
4.1 months as second-line and beyond, including a small
number of patients who had received pemetrexed [13]. In
addition, a previous study which compared efficacy of
pemetrexed in relation to gene mutation reported that
EGFR mutation was not associated with survival gain [5].
Accordingly, our present study demonstrated that patients
with EGFR mutations were unlikely to benefit from peme-
trexed therapy. On the other hand, previous studies re-
ported that treatment outcomes which included PFS and
the response rate for pemetrexed in NSCLC cases with
ALK translocation were better than the patients with a
wild-type for ALK [5, 14, 15]. However, other previous
studies did not report any benefit of pemetrexed in
NSCLC patients with ALK translocation [7, 16]. Our
current study findings suggest that ALK translocation may
be an indicator for the response to pemetrexed therapy, al-
though it was not demonstrated in multivariate analysis.
Since only 3 patients in our current study had received cri-
zotinib prior to pemetrexed therapy, we could not investi-
gate whether crizotinib could affect on treatment outcome
of pemetrexed. However, we could assume that peme-
trexed could be considered as second-line or a good alter-
native to crizotinib in patients with ALK translocation.
The number of metastatic site was also prognostic factor
predicting efficacy of pemetrexed. In our present study, a
larger proportion of good responders experienced recur-
rence after surgical therapy compared with poor re-
sponders. Because the patients who had received surgical
therapy underwent regular follow-up assessments using
Table 1 Baseline patient characteristics
Total (n = 314) Good responders (n = 92) Poor responders (n = 222) P-value
Age, years, mean ± SD 59.1 ± 10.1 59.2 ± 10.1 59.1 ± 10.1 0.953
Sex, Female 145 (46.2) 53 (57.6) 92 (41.4) 0.009
History of smoking (n = 303) 303 86 217 0.015
Current smoker 68 (22.4) 12 (14.0) 56 (25.8)
Ex-smoker 76 (25.1) 18 (20.9) 58 (26.7)
Never smoker 159 (52.5) 56 (65.1) 103 (47.5)
Stage 0.456
≤IIIB 19 (6.1) 7 (7.6) 12 (5.4)
IV 295 (93.9) 85 (92.4) 210 (94.6)
Stage M1a 93 (29.6) 44 (47.8) 49 (22.1) <0.001
Stage M1b 202 (64.3) 41 (44.6) 161 (72.5) <0.001
Type of chemotherapy 0.002
Pemetrexed monotherapy 263 (83.8) 68 (73.9) 195 (87.8)
Pemetrexed combination 51 (16.2) 24 (26.1) 27 (12.2) 0.552
Platinum 34 (10.8) 15 (16.3) 19 (8.6)
Non-platinum 17 (5.4) 9 (9.8) 8 (3.6)
Previous chemotherapy 0.068
0 44 (14.0) 18 (19.6) 26 (11.7)
≥1 270 (86.0) 74 (80.4) 196 (88.3)
Previous regimen (n = 270)a 270 74 196
Response to Gemcitabineb 88/175 (50.3) 32/49 (65.3) 56/126 (44.4) 0.013
Response to EGFR-TKI 79/128 (61.7) 16/34 (47.1) 63/94 (67.0) 0.040
Response to Paclitaxel 36/56 (64.3) 5/14 (35.7) 31/42 (73.8) 0.010
Response to Docetaxel 7/14 (50.0) 4/6 (66.7) 3/8 (37.5) 0.592
Response to Miscellaneous 7/15 (46.7) 3/4 (75.0) 4/11 (36.4) 0.282
Data are shown as n (%) per each group, unless otherwise noted
aTotal number exceeds 270 as some patients had received two or more regimen prior to pemetrexed
bResponse was defined as achievement of partial response or stable disease for 3 months or more. Others were defined as non-response
SD standard deviation, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor
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chest computer tomography, they tended to show a low
tumor burden. Furthermore, the good responders had
fewer distant metastatic lesions when the cancer recurred
after surgical resection. Additionally, a prospective study
by Sanchez et al. reported that the numbers of metastatic
sites and lesions had prognostic relevance [17]. Tumor
burden has exhibited prognostic relevance for survival ir-
respective of therapeutic agents, cytotoxic chemotherapy,
and use of a tyrosine kinase inhibitor such as gefitinib
[18–20]. Zhao et al., reported that cancer cells can tolerate
chemotherapy and acquire more stemness under hypoxic
conditions [21]. Additionally, cells expressing CD166, a
specific membrane molecule expressed in cancer stem
cells, exhibited a higher survival rate against pemetrexed
under hypoxic conditions [21]. We assume that this may
explain the poor outcomes in NSCLC patients with a
Table 2 Histological and genetic characteristics of the patients treated with a pemetrexed-containing therapy
Total (n = 314) Good responders (n = 92) Poor responders (n = 222) P-value
Histology 0.810
Adenocarcinoma 285 (90.8) 83 (90.2) 202 (91.0)
Large cell carcinoma 5 (1.6) 2 (2.2) 3 (1.4)
NSCLC-NOS 24 (7.6) 7 (7.6) 17 (7.7)
Subtype (n = 57)* 57 24 33 0.368
Mucinous 22 (38.6) 10 (41.7) 12 (36.4)
Acinar 13 (22.8) 7 (29.2) 6 (18.2)
Papillary 13 (22.8) 4 (16.7) 9 (27.3)
Signet-ring 5 (8.8) 3 (12.5) 2 (6.1)
Solid 4 (7.0) 0 4 (12.1)
Differentiation (n = 220) 220 63 157 0.001
Well-differentiated 18 (8.2) 12 (19.0) 6 (3.8)
Moderately-differentiated 115 (52.3) 29 (46.0) 86 (54.8)
Poorly-differentiated 87 (39.5) 22 (34.9) 65 (41.4)
TTF-1 expression (n = 151) 125 (82.8) 35 (94.6) 90 (78.9) 0.028
Gene mutation (n = 239) 239 72 167
EGFR mutation 89 (37.2) 12 (16.7) 77 (46.1) <0.001
ALK translocation 23 (9.6) 16 (22.2) 7 (4.2) <0.001
KRAS mutation 5 (2.1) 0 5 (3.0) 0.326
Wild-type for EGFR/ALK/KRAS 122 (51.0) 44 (61.1) 78 (46.7) 0.041
Data are shown as n (%) per each group, unless otherwise noted *The subtype was not subclassified according to the International Association for the Study of
Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung adenocarcinoma revised at 2011, for study subjects were recruited
from 2006
NSCLC-NOS Non-small-cell lung cancer-not otherwise specified; TTF-1 thyroid transcription factor-1; EGFR epidermal growth factor receptor; ALK anaplastic
lymphoma kinase; KRAS Kirsten rat sarcoma viral oncogene homolog
Table 3 Number and site of metastases in the patients treated with a pemetrexed-containing therapy
Total (n = 314) Good responder (n = 92) Poor responder (n = 222) P-value
Number of metastatic sites ≥2 201 (64.0) 44 (47.8) 157 (70.7) <0.001
Site of metastases
Lung 152 (48.4) 48 (52.2) 104 (46.8) 0.390
Pleura 144 (45.9) 39 (42.4) 105 (47.3) 0.427
Bone 125 (39.8) 29 (31.5) 96 (43.2) 0.053
Brain 77 (24.5) 18 (19.6) 59 (26.6) 0.189
Adrenal gland 45 (14.3) 3 (3.3) 42 (18.9) <0.001
Liver 43 (13.7) 5 (5.4) 38 (17.1) 0.006
Pericardial effusion 20 (6.4) 5 (5.4) 15 (6.8) 0.662
Previous surgical therapy 68 (21.7) 37 (40.2) 31 (14.0) <0.001
Data are shown as n (%) per each group, unless otherwise noted
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higher tumor burden because disseminated tumors reflect
both the rapid growth of cancer cells and greater number
of cancer cells under relatively hypoxic conditions. Along
with tumor burden, metastatic sites in our current pa-
tients were correlated with their prognoses. Similar to
previous studies that demonstrated a correlation of metas-
tases to the brain, bone and liver with a poor prognosis,
our current data indicates that presence of intraabdominal
metastasis significantly correlate with a poor response to
pemetrexed [19, 22–24]. In addition, the metastatic lesion
to liver, adrenal gland and bone also affected negatively on
response to pemetrexed according to results by univariate
analysis.
Lastly, never-smoking status was associated with good
response to pemetrexed. This has been suggested in sev-
eral previous studies, therefore, smoking status should
be considered an important factor when choosing the
treatment regimen [5, 7].
In the good responder group, 46.7 % of patients
showed a partial response, while 53.3 % of patients ex-
hibited stable disease. Achievement of a response is a
robust marker of a biological therapeutic effect and cor-
relates with both PFS and overall survival [25, 26]. Al-
though the response rate was higher than the 9.1 % rate
observed for overall pemetrexed monotherapy previ-
ously, it need to be noted that a large number of pa-
tients who have received pemetrexed for a long
period of time without disease progression could not
achieve a response [3].
The present study has several limitations. First, it had
a retrospective design and patients did not receive treat-
ment according to an established protocol which led to
differences in the treatment regimens. Significantly more
patients in the good responder group received peme-
trexed in combination with other agent than the poor
responder group (26.1 % versus 12.2 %, P = 0.002). How-
ever, the univariate analysis showed that the treatment
option was not a prognostic factor (HR, 0.803; 95 % CI,
0.575–1.120; P = 0.196). In addition, Sun et al. reported
that prior chemotherapeutic regiment and its response
influence the efficacy of pemetrexed therapy [27]. As
presented in Table 1, there was significant difference in
response to gemcitabine and EGFR-tyrosine kinase in-
hibitor between two groups, while, the response of prior
chemotherapeutic regimen did not affect on efficacy of
pemetrexed according to univariate analysis. Second, we
could not identify the exact performance status of each
patient when they received pemetrexed. Many previous
studies have reported that performance status represents
an important prognostic factor, so it could also have af-
fected the prognosis of our present cases [28–31]. Third,
we compared two groups by extracting the top 5 % and
the bottom 12 % of patients from the initial patient
Fig. 2 Prognostic factors by univariate analysis. The Forest plot of prognostic factors for non-small-cell lung cancer patients treated with
pemetrexed-containing therapy. The Forest plot shows the hazard ratio and 95 % confidence interval of the prognostic factors by univariate
analysis. W/D well-differentiated cancer; EGFR epidermal growth factor receptor; ALK anaplastic lymphoma kinase; KRAS Kirsten rat sarcoma viral
oncogene homolog; CI confidence interval
Table 4 Prognostic factors predicting the efficacy of
pemetrexed in patients with non-squamous non-small-cell lung
cancer assessed using a multivariate Cox model
Characteristics Hazard ratio (95 % CI) P-value
Never-smoker 1.997 (1.442–2.766) <0.001
Metastasis to intraabdomen 0.590 (0.410–0.847) 0.004
Number of metastatic lesion ≥2 0.668 (0.471–0.946) 0.023
Presence of EGFR mutation 0.520 (0.377–0.718) <0.001
CI confidence interval; EGFR epidermal growth factor receptor
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population. Because this was not an enumeration study,
the study design itself could have introduced a bias.
However, we selected the top 5 % since the section be-
tween approximately 5–6 % was sharply changing when
patients arranged in order of duration of pemetrexed ther-
apy (Fig. 1). To show a clear contrast between two groups,
we selected two sections in the top and bottom 5 % al-
though the proportion of poor responders increased to
12 % for their same amount of pemetrexed usage.
Conclusions
In conclusion, factors such as smoking status, genetic
alteration status, intra-abdominal metastasis, and tumor
burden may be considered as predictive factors for the re-
sponse to pemetrexed therapy in non-squamous NSCLC.
Abbreviations
ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor;
HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC,
non-small-cell lung cancer; PFS, progression-free survival; SD, stable disease;
TS, thymidylate synthase; TTF-1, thyroid transcription factor-1
Acknowledgements
This study was supported by the Basic Science Research Program through
the National Research Foundation of Korea (NRF, grant 2013R1A1A2005112
to JKR and grant 2014R1A2A2A01003438 to JCL) and a grant (2014-597) from
Asan Institute for Life Sciences, Seoul, South Korea.
Funding
None.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
SP had full access to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis. JCL contributed to
the design of the study and the final review of the manuscript. HJK contributed
to the design of the study. CMC, DHL, SWK, JSL, WSK and SHC contributed to
subject recruitment. JKR contributed data analysis and drafting. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study design was approved by the Institutional Review Board of Asan
Medical Center, which waived the requirement for informed consent due to
the retrospective nature of the analysis.
Author details
1Department of Pulmonary and Critical Care Medicine, University of Ulsan,
College of Medicine, Asan Medical Center, 388-1 Pungnap–Dong,
Songpa-gu, Seoul 05505, South Korea. 2Department of Internal Medicine,
Kyungpook National University Hospital, Kyungpook National University
School of Medicine, 130 Dongdeok-ro, Jung-gu, Daegu 41944, South Korea.
3Department of Oncology, University of Ulsan, College of Medicine, Asan
Medical Center, 388-1 Pungnap–Dong, Songpa-gu, Seoul 05505, South Korea.
4Department of Thoracic and Cardiovascular Surgery, University of Ulsan,
College of Medicine, Asan Medical Center, 388-1 Pungnap–Dong,
Songpa-gu, Seoul 05505, South Korea. 5Asan Institute for Life Sciences, Asan
Medical Center, 388-1 Pungnap–Dong, Songpa-gu, Seoul 05505, South Korea.
Received: 3 November 2015 Accepted: 24 June 2016
References
1. Jung KW, Won YJ, Kong HJ, Oh CM, As S, Lee JS. Survival of Korean Adult
Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry
Study. Cancer Res Treat. 2013;45:162–71.
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C,
et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin
plus pemetrexed in chemotherapy-naive patients with advanced-stage non-
small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.
3. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et
al. Randomized phase III trial of pemetrexed versus docetaxel in patients
with non-small-cell lung cancer previously treated with chemotherapy.
J Clin Oncol. 2004;22:1589–97.
4. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH,
et al. Phase III study by the Norwegian lung cancer study group:
pemetrexed plus carboplatin compared with gemcitabine plus carboplatin
as first-line chemotherapy in advanced non-small-cell lung cancer.
J Clin Oncol. 2009;27:3217–24.
5. Park S, Park TS, Choi CM, Lee DH, Kim SW, Lee JS, et al. Survival Benefit of
Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma
Kinase Gene Rearrangements. Clin Lung Cancer. 2015;16:e83–9.
6. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line
crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J
Med. 2014;371:2167–77.
7. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson
M, et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-
positive non-small cell lung cancer. Ann Oncol. 2013;24:59–66.
8. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase
and thyroid transcription factor 1 expression in patients with nonsquamous
non-small cell lung cancer treated with pemetrexed-based chemotherapy.
J Thorac Oncol. 2011;6:1392–9.
9. Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H.
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients
with advanced non–small-cell lung cancer receiving pemetrexed plus
carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
J Thorac Oncol. 2013;8:1255–64.
10. Mou W, Xue H, Tong H, Sun S, Zhang Z, Zhang C, et al. Prognostic value of
serum leptin in advanced lung adenocarcinoma patients with cisplatin/
pemetrexed chemotherapy. Oncol Lett. 2014;7:2073–8.
11. Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, Do Nascimento YN,
et al. Randomized phase III trial of single-agent pemetrexed versus
carboplatin and pemetrexed in patients with advanced non-small-cell lung
cancer and Eastern Cooperative Oncology Group performance status of 2.
J Clin Oncol. 2013;31:2849–53.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer. 2009;45:228–47.
13. Paz-Ares L, Soulieres D, Moecks J, Bara I, Mok T, Klughammer B. Pooled
analysis of clinical outcome for EGFR TKI-treated patients with EGFR
mutation-positive NSCLC. J Cell Mol Med. 2014;18:1519–39.
14. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, et al.
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung
cancer are associated with prolonged progression-free survival on
pemetrexed. J Thorac Oncol. 2011;6:774–80.
15. Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, et al. Anaplastic
lymphoma kinase translocation: a predictive biomarker of pemetrexed in
patients with non-small cell lung cancer. J Thorac Oncol. 2011;6:1474–80.
16. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib
versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med.
2013;368:2385–94.
17. Sanchez De Cos Escuin J, Abal Arca J, Melchor Iniguez R, Miravel Sorribes L,
Nunez Ares A, Hernandez Hemandez JR, et al. Tumor, node and metastasis
classification of lung cancer–M1a versus M1b–analysis of M descriptors and
other prognostic factors. Lung Cancer. 2014;84:182–9.
18. Joss RA, Burki K, Dalquen P, Schatzmann E, Leyvraz S, Cavalli F, et al.
Combination chemotherapy with mitomycin, vindesine, and cisplatin for
non-small cell lung cancer. Association of antitumor activity with initial
tumor burden and treatment center. Cancer. 1990;65:2426–34.
Park et al. BMC Cancer  (2016) 16:417 Page 7 of 8
19. Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, et al. Number of
metastatic sites is a strong predictor of survival in patients with nonsmall
cell lung cancer with or without brain metastases. Cancer. 2009;115:2930–8.
20. Park JH, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, et al. Tumor burden is
predictive of survival in patients with non-small-cell lung cancer and with
activating epidermal growth factor receptor mutations who receive
gefitinib. Clin Lung Cancer. 2013;14:383–9.
21. Zhao M, Zhang Y, Zhang H, Wang S, Zhang M, Chen X, et al. Hypoxia-
induced cell stemness leads to drug resistance and poor prognosis in lung
adenocarcinoma. Lung Cancer. 2015;87:98–106.
22. Fujimoto D, Ueda H, Shimizu R, Kato R, Otoshi T, Kawamura T, et al. Features
and prognostic impact of distant metastasis in patients with stage IV lung
adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
Clin Exp Metastasis. 2014;31:543–51.
23. Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al.
Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78–84.
24. Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung JY, Yen CJ, et al. Liver metastasis
predicts poorer prognosis in stage IV lung adenocarcinoma patients
receiving first-line gefitinib. Lung Cancer. 2015;88:187–94.
25. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault‐Goebel F, Krulik
M. Correlation between progression free survival and response rate in
patients with metastatic colorectal carcinoma. Cancer. 2001;91:2033–8.
26. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al.
Response rate or time to progression as predictors of survival in trials of
metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.
Lancet Oncol. 2006;7:741–6.
27. Sun JM, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, et al. The relationship
between response to previous systemic treatment and the efficacy of
subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Lung Cancer. 2010;68:427–32.
28. Bittner N, Baliko Z, Sarosi V, Laszlo T, Toth E, Kasler M, et al. Bone Metastases
and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma - The
Results of Three Year Retrospective Analysis. Pathol Oncol Res. 2015;21:
1217–21.
29. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. The impact
of additional prognostic factors on survival and their relationship with the
anatomical extent of disease expressed by the 6th Edition of the TNM
Classification of Malignant Tumors and the proposals for the 7th Edition.
J Thorac Oncol. 2008;3:457–66.
30. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al.
Performance status and smoking status are independent favorable
prognostic factors for survival in non-small cell lung cancer: a
comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol.
2010;5:620–30.
31. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in
extensive-stage non-small-cell lung cancer: the Southwest Oncology Group
experience. J Clin Oncol. 1991;9:1618–26.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Park et al. BMC Cancer  (2016) 16:417 Page 8 of 8
